BIOMARIN PHARMACEUTICAL INC (BMRN)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, BIOMARIN PHARMACEUTICAL INC reported revenue of $3.22B, up 12.9% from the prior year. The company was profitable, with a net margin of 10.8%. It held $7.59B in total assets against $1.51B in total liabilities.
Key ratios (FY2025)
12.7%
Operating margin
10.8%
Net margin
5.7%
Return on equity
+12.9%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B | $1.86B | $1.70B | $1.49B | $1.31B | $1.12B |
| Cost of Revenue | $717.44M | $580.24M | $532.06M | $503.02M | $470.51M | $524.27M | $359.47M | $315.26M | $241.79M | $209.62M |
| Operating Income | $409.48M | $484.21M | $185.77M | $160.97M | -$82.34M | -$43.44M | -$100.46M | -$123.52M | -$14.70M | -$803.43M |
| Net Income | $348.90M | $426.86M | $167.65M | $141.56M | -$64.08M | $854.03M | -$23.85M | -$77.21M | -$117.04M | -$630.21M |
| EPS (Diluted) | $1.80 | $2.21 | $0.87 | $0.75 | $-0.35 | $4.50 | $-0.13 | $-0.44 | $-0.67 | $-3.81 |
| Total Assets | $7.59B | $6.99B | $6.84B | $6.38B | $6.00B | $5.85B | $4.69B | $4.43B | $4.63B | $4.02B |
| Total Liabilities | $1.51B | $1.33B | $1.89B | $1.77B | $1.74B | $1.74B | $1.57B | $1.46B | $1.82B | $1.26B |
| Shareholders' Equity | $6.09B | $5.66B | $4.95B | $4.60B | $4.27B | $4.10B | $3.12B | $2.97B | $2.81B | $2.77B |
| Cash & Equivalents | $1.31B | $942.84M | $755.13M | $724.53M | $587.28M | $649.16M | $437.45M | $493.98M | $598.03M | $408.33M |
| Operating Cash Flow | $827.99M | $572.84M | $159.26M | $175.90M | $304.54M | $85.36M | $48.26M | $20.21M | -$8.76M | -$227.84M |
| Capital Expenditures | $103.04M | $85.42M | $96.69M | $120.96M | $95.58M | $114.31M | $145.03M | $144.62M | $199.22M | $148.38M |
| Shares Outstanding | 192.30M | 190.76M | 188.60M | 186.25M | 183.91M | 181.74M | 179.84M | 178.25M | 175.84M | 172.65M |